Synapticure, a telemedicine company focused on people and caregivers living with neurodegenerative diseases, announced it has raised $25 million in a Series A funding round led by B Capital.
New investors CVS Health Ventures, RA Capital Management, CommonSpirit Health and Nexus NeuroTech Ventures participated in the round, with participation from existing investors Google Ventures, Rock Health Capital and Optum Ventures.
WHAT IT DOES
Synapticure is a virtual care company that provides treatment for individuals with neurodegenerative diseases, such as ALS, Alzheimer’s, Parkinson’s and Huntington’s disease. It also offers mental health support, genetic testing and guidance related to clinical trials.
The company will use the funds to expand its partnerships with healthcare payers and providers, advance its technology platform, accelerate clinical research and scale nationally.
“This investment will enable Synapticure to continue to democratize care for people and their families living with neurodegenerative diseases,” Sandra Abrevaya, cofounder and CEO of Synapticure, said in a statement.
“With the support of B Capital as well as both new and existing blue-chip investors, I am proud Synapticure works to reach patients in any community across the U.S. living with one of these conditions so they can receive the expert, personalized specialty care they deserve.”
MARKET SNAPSHOT
In 2022, the Chicago-based company launched with $6 million in seed funding in a round led by Google Ventures (GV).
The company was founded by Sandra Abrevaya, its current CEO, and her husband, Brian Wallach, an ALS patient and former assistant United States attorney in the Northern District of Illinois and senior vetting counsel in the Obama administration.
In August, Synapticure announced its partnership with Pearl Health, a technology company centered on physician enablement in value-based care in order to provide personalized support to Medicare patients with dementia. The collaboration intends to benefit dementia patients and their families through the CMS GUIDE program.
Earlier this year, the company announced a partnership with the ALS Association to offer its telehealth platform as a supplement to in-person care at ALS Certified Treatment Centers of Excellence and Recognized Treatment Centers.
